Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
12 pending office actions • 8 clients • 10 examiners • 8 art units • 0 of 12 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
LOWRY BLIXSETH APC has managed 420 career applications in the Biotechnology and Pharmaceuticals technology area. The firm currently has 7 pending office actions. This career volume of 420 applications shows a practice in this technical and regulated field.
The firm maintains a resolved allowance rate of 91.7 percent. It takes an average of 3.24 office actions per allowance to reach a successful outcome. This 3.24 average office actions per allowance indicates the typical prosecution cycle for its 420 career applications. The 91.7 percent allowance rate serves as a performance metric for its work in Biotechnology and Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 7 (58%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KATCHEVES, BASIL S | 2 | 72.2% | +17.4% |
| TUROCY, DAVID P | 2 | 46.9% | +35.5% |
| WOODALL, NICHOLAS W | 1 | 82.0% | +13.3% |
| GINES, GEORGE SAMUEL | 1 | 69.5% | +40.5% |
| LEE, SHIN | 1 | 66.7% | +100.0% |
| HOEKSTRA, JEFFREY GERBEN | 1 | 56.5% | +39.1% |
| COHEN, MICHAEL P | 1 | 58.7% | +27.5% |
| TRUONG, QUANGLONG N | 1 | 78.8% | +23.6% |
| COCHRAN, KARI LEE | 1 | 100.0% | +0.0% |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | WOODALL, NICHOLAS W | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18198240 | UNIVERSAL TIBIAL INSERT WITH ENHANCED MEDIAL CONGRUENCE | COCHRAN, KARI LEE | 22d overdue |
| 19014120 | TRI-LAYER BED COVER | GINES, GEORGE SAMUEL | 23d |
| 18869773 | SYSTEM AND METHOD FOR EVALUATING BEDSORE RISK | HOEKSTRA, JEFFREY GERBEN | — |
| 17267166 | NANOPARTICLES FOR TRANSFECTION | EBBINGHAUS, BRIANA NOEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427813 | SLAB SUPPORT | KATCHEVES, BASIL S | 49d overdue |
| 19351176 | SLAB SUPPORT | KATCHEVES, BASIL S | 23d overdue |
| 18438087 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | COHEN, MICHAEL P | 8d overdue |
| 19014120 | TRI-LAYER BED COVER | GINES, GEORGE SAMUEL | 23d |
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | WOODALL, NICHOLAS W | — |
| 19201758 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL SILICON NITRIDE LAYER APPLIED VIA BOMBARDMENT | TUROCY, DAVID P | — |
| 18983324 | PROCESSES AND SYSTEMS FOR HEADPHONE TUNING | LEE, SHIN | — |
| 18869773 | SYSTEM AND METHOD FOR EVALUATING BEDSORE RISK | HOEKSTRA, JEFFREY GERBEN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| JOINT DEVELOPMENT, INC. | 4 |
| SafeBoard LLC | 2 |
| Keeco, LLC | 1 |
| Yellow Matter Entertainment, LLC | 1 |
| Neo Able Co., Ltd. | 1 |
| Invion, Inc. | 1 |
| Chronic Airway Therapeutics Limited | 1 |
| Loxegen Holdings Pty Ltd. | 1 |
| Art Unit | Apps |
|---|---|
| 3633 | 2 |
| 3775 | 1 |
| 3673 | 1 |
| 1612 | 1 |
| 1624 | 1 |
| 3774 | 1 |
| 1718 | 1 |
| 1632 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19351176 | SLAB SUPPORT | Safeboard LLC | KATCHEVES, BASIL S | 3633 | §103 | Non-Final OA | 23d overdue | Pending | Oct 06, 2025 |
| 19241099 | UNIBODY ORTHOPEDIC SURGICAL INSTRUMENT | Joint Development, Inc. | WOODALL, NICHOLAS W | 3775 | §103 | Non-Final OA | — | Pending | Jun 17, 2025 |
| 19201758 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL SILICON NITRIDE LAYER APPLIED VIA BOMBARDMENT | Joint Development, Inc. | TUROCY, DAVID P | §103DP | Non-Final OA | — | Pending | May 07, 2025 | |
| 19014120 | TRI-LAYER BED COVER | Keeco, LLC | GINES, GEORGE SAMUEL | 3673 | §102§103 | Non-Final OA | 23d | Pending | Jan 08, 2025 |
| 18983324 | PROCESSES AND SYSTEMS FOR HEADPHONE TUNING | Yellow Matter Entertainment, LLC | LEE, SHIN | §103 | Non-Final OA | — | Pending | Dec 16, 2024 | |
| 18869773 | SYSTEM AND METHOD FOR EVALUATING BEDSORE RISK | Neo Able Co., Ltd. | HOEKSTRA, JEFFREY GERBEN | §101§102§112 | Non-Final OA | — | Pending | Nov 26, 2024 | |
| 18438087 | USE OF BETA-ADRENERGIC INVERSE AGONISTS FOR SMOKING CESSATION | Invion, Inc. | COHEN, MICHAEL P | 1612 | §103 | Final Rejection | 8d overdue | Pending | Feb 09, 2024 |
| 18427813 | SLAB SUPPORT | Safeboard LLC | KATCHEVES, BASIL S | 3633 | §103 | Final Rejection | 49d overdue | Pending | Jan 30, 2024 |
| 18281135 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited | TRUONG, QUANGLONG N | 1624 | §103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18198240 | UNIVERSAL TIBIAL INSERT WITH ENHANCED MEDIAL CONGRUENCE | Joint Development, LLC | COCHRAN, KARI LEE | 3774 | §102§103 | Final Rejection | 22d overdue | Pending | May 16, 2023 |
| 17713791 | PROCESSES FOR PRODUCING ORTHOPEDIC IMPLANTS HAVING A SUBSURFACE LEVEL CERAMIC LAYER APPLIED VIA BOMBARDMENT | Joint Development, LLC | TUROCY, DAVID P | 1718 | §103 | Final Rejection | — | Pending | Apr 05, 2022 |
| 17267166 | NANOPARTICLES FOR TRANSFECTION | Loxegen Holdings Pty Ltd. | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112Other | Non-Final OA | — | Pending | Feb 09, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial